the aim of this investigation was to design and develop nanoemulsions (nes) as novel ophthalmic delivery systems for brinzolamide (bzd). phase behavior of quaternary systems composed of triacetin and capryoltm 90 (selected oils, screened through the solubility studies), various surfactants (namely, cremophor rh 40, brij 35, labrasol and tyloxapol), transcutol p (as co-surfactant) and water a...

The aim of this investigation was to design and develop nanoemulsions (NEs) as novel ophthalmic delivery systems for brinzolamide (BZD). Phase behavior of quaternary systems composed of triacetin and CapryolTM 90 (selected oils, screened through the solubility studies), various surfactants (namely, Cremophor RH 40, Brij 35, Labrasol and tyloxapol), Transcutol P (as co-surfactant) an...

Brinzolamide (BZ) is an intraocular pressure reducing agent with low bioavailability. The purpose of the present study was to overcome this issue by development of BZ containing nanoemulsions (NEs) as an ocular drug delivery system with desirable therapeutic efficacy. Brinzolamide NEs were prepared by the spontaneous emulsification method. Based on initial release studies, twelve formulations w...

Brinzolamide (BZ) is an intraocular pressure reducing agent with low bioavailability. The purpose of the present study was to overcome this issue by development of BZ containing nanoemulsions (NEs) as an ocular drug delivery system with desirable therapeutic efficacy. Brinzolamide NEs were prepared by the spontaneous emulsification method. Based on initial release studies, twelve formulations w...

A sensitive and fast UV spectrophotometric technique and feasible reverse phase liquid chromatographic method for the analysis of Brinzolamide and Brimonidine tartrate in ophthalmic formulation has been developed. Linearity ranges for both methods were 5 25 ìg/ml and 1-5 ìg/ml for brinzolamide and brimonidine tartrate respectively. The absorption maxima were observed at 232 and 257 nm for Brinz...

Brinzolamide (BZ) is an intraocular pressure reducing agent with low bioavailability. The purpose of the present study was to overcome this issue by development of BZ containing nanoemulsions (NEs) as an ocular drug delivery system with desirable therapeutic efficacy. Brinzolamide NEs were prepared by the spontaneous emulsification method. Based on initial release studies, twelve formulations w...

the aim of this study is to formulate a novel ophthalmic nanosuspension (ons), an alternative carrier system to traditional colloidal carriers for controlled release (cr) of acyclovir (acv). in the present study, ons is employed to avoid some of major disadvantages of colloidal carriers systems such as instability in cul de sac and short half life by increasing efficiency of drug encapsulation ...

To investigate the effect of brinzolamide on diurnal fluctuations in the intraocular pressure (IOP) in patients on latanoprost ophthalmic solution prospectively was aimed. Eleven patients with primary open angle glaucoma were enrolled in this study. The subjects were admitted to the hospital and had their IOPs measured over 24 hours (10 AM, noon, 2 PM, 4 PM, 6 PM, 8 PM, 10 PM, midnight, 3 AM, 6...

Ophthalmic In-situ gels are viscous polymer‐based liquids that exhibit sol‐to‐gel phase transition on the ocular surface due to change in a specific physicochemical parameter like ionic strength, pH or temperature Gel dosage forms are successfully used as drug delivery systems considering their ability to prolong the drug release. To prolong the precorneal resident time and improve ocular bioav...

objective(s) several antigens, adjuvants and delivery systems have been evaluated for induction of protective immune responses against leishmaniasis, but most of them have been inefficient. in this study, plga nanospheres as antigen delivery system cpg-odn as an immunoadjuvant for increasing the immune responses against autoclaved leishmania major (alm) were prepared and characterized. material...